Wajed Abarah

Meaux, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Analytical validation and clinical concordance of Diazyme free light chain assays on the Cobas® platform compared with Freelite™.

Analytical validation and clinical concordance of Diazyme free light chain assays on the Cobas® platform compared with Freelite™.

Journal: Annales de biologie clinique
Published: June 10, 2026

Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study.

Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: March 11, 2025

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.

Journal: Blood
Published: September 16, 2024

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 16, 2024

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.

Journal: Pharmaceutics
Published: June 29, 2022

Hidden in the Eyes-Recurrence of Systemic Hemopathies Reportedly "In Remission": Six Cases and Review of Literature.

Hidden in the Eyes-Recurrence of Systemic Hemopathies Reportedly "In Remission": Six Cases and Review of Literature.

Journal: Medicina (Kaunas, Lithuania)
Published: January 12, 2022

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.

Journal: Oncotarget
Published: April 06, 2016

Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.

Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.

Journal: Haematologica
Published: February 27, 2015

Isolated bone marrow Hodgkin lymphoma in a human immunodeficiency virus-negative patient: a second case.

Isolated bone marrow Hodgkin lymphoma in a human immunodeficiency virus-negative patient: a second case.

Journal: Leukemia & lymphoma
Published: September 28, 2013
Showing 1-9 of 9

Last Updated: 09/26/2026